Stoke Therapeutics (STOK) Long-Term Investments (2024 - 2026)

Stoke Therapeutics' Long-Term Investments history runs 3 years deep, the most recent figure standing at $67.5 million for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 193.54% year-over-year to $67.5 million in Q1 2026; TTM through Mar 2026 was $67.5 million, a 193.54% increase from a year earlier, with the FY2025 full-year figure at $106.3 million, up 256.29% from the prior year.
• Long-Term Investments fell to $67.5 million in Q1 2026 per STOK's latest filing, from $106.3 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $107.3 million in Q2 2025 and bottomed at $23.0 million in Q1 2025.
• The 3-year median for Long-Term Investments is $67.5 million (2026), against an average of $63.4 million.
• Biggest YoY gain for Long-Term Investments was 256.29% in 2025; the steepest drop was 168.15% in 2025.
• Year by year, Long-Term Investments stood at $29.8 million in 2024, then surged by 256.29% to $106.3 million in 2025, then slumped by 36.49% to $67.5 million in 2026.
• Per Business Quant, the three latest STOK Long-Term Investments figures stand at $67.5 million (Q1 2026), $106.3 million (Q4 2025), and $80.3 million (Q3 2025).